The combination of
gemfibrozil and
repaglinide results in a marked pharmacokinetic interaction that can result in serious hypoglycaemia.
On the basis of studies and reports of serious hypoglycaemic episodes with
gemfibrozil and
repaglinide, the European Medicines Agency contraindicate concurrent use.